The DOI matches its Crossref record.
Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity
Abstract
Several camptothecin derivatives containing a modified hydroxy lactone ring have been synthesized and evaluated for inhibition of topoisomerase I and cytotoxicity to mammalian cells. Each of the groups of the hydroxy lactone moiety, the carbonyl oxygen, the ring lactone oxygen, and the 20-hydroxy group, were shown to be critical for enzyme inhibition. For example the lactol, lactam, thiolactone, and 20-deoxy derivatives did not stabilize the covalent DNA-topoisomerase I complex. With a few exceptions, those compounds that did not inhibit topoisomerase I were not cytotoxic to mammalian cells. Two cytotoxic derivatives that did not inhibit topoisomerase I were shown to produce non-protein-associated DNA single-strand breaks and are likely to have a different mechanism of action. One of these compounds was tested for antitumor activity and was found to be inactive. The present findings, as well as other reports that the hydroxy lactone ring of camptothecin is critical for antitumor activity in vivo, correlate with the structure-activity relationships at the level of topoisomerase I and support the hypothesis that antitumor activity is related to inhibition of this target enzyme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs
Lu, J., Liong, M., Zink, J. I., & Tamanoi, F. (2007) · Small · doi:10.1002/smll.200700005 · Cited by 1,012
Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., & Hol, W. G. J. (1998) · Science · doi:10.1126/science.279.5356.1504 · Cited by 889
The mechanism of topoisomerase I poisoning by a camptothecin analog
Staker, B. L., Hjerrild, K., Feese, M. D., Behnke, C. A., Burgin, A. B., & Stewart, L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242259599 · Cited by 818
DNA Topoisomerases: Essential Enzymes and Lethal Targets
Chen, A. Y., & Liu, L. F. (1994) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.34.040194.001203 · Cited by 737
Mechanized Silica Nanoparticles: A New Frontier in Theranostic Nanomedicine
Ambrogio, M. W., Thomas, C. R., Zhao, Y.-L., Zink, J. I., & Stoddart, J. F. (2011) · Accounts of Chemical Research · doi:10.1021/ar200018x · Cited by 604
Cancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature
Venditto, V. J., & Simanek, E. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900243b · Cited by 452
Camptothecin: current perspectives
Thomas, C. J., Rahier, N. J., & Hecht, S. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.11.036 · Cited by 451
Topoisomerase-targeting antitumor drugs
D'Arpa, P., & Liu, L. F. (1989) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(89)90041-3 · Cited by 434
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons
Huang, H.-S., Allen, J. A., Mabb, A. M., King, I. F., Miriyala, J., Taylor-Blake, B., Sciaky, N., Dutton, J. W., Lee, H.-M., Chen, X., et al. (2012) · Nature · doi:10.1038/nature10726 · Cited by 387
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., & Kaufmann, S. H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.647 · Cited by 353
Phase I and pharmacokinetic trial of weekly CPT-11.
Rothenberg, M. L., Kuhn, J. G., Burris, H. A., Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., & Rodriguez, G. I. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2194 · Cited by 301
Camptothecins: A Review of Their Chemotherapeutic Potential
Ulukan, H., & Swaan, P. W. (2002) · Drugs · doi:10.2165/00003495-200262140-00004 · Cited by 299
Injectable chitosan hydrogels for localised cancer therapy
Ta, H. T., Dass, C. R., & Dunstan, D. E. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.11.018 · Cited by 287
Amin, A., Halabi, S., Gelmann, E. P., Stadler, W., Vogelzang, N., & Small, E. (2004) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2004.05.002 · Cited by 9
Metadata
- Authors
- Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K., & Kingsbury, W. D.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1989-03
- Volume
- 32
- Issue
- 3
- Pages
- 715-720
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1997361520
- Cited by
- 413
- References
- 0
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.